Table 2.
NIVO+RELA (n=50) |
||
Investigator assessed | BICR assessed | |
Objective response rate, n (%) | 25 (50) | 24 (48) |
95% CI | 35.5 to 64.5 | 33.7 to 62.6 |
Best overall response, n (%) | ||
Complete response | 5 (10) | 8 (16) |
Partial response | 20 (40) | 16 (32) |
Stable disease | 12 (24) | 11 (22) |
Progressive disease | 13 (26) | 14 (28) |
Unable to determine | 0 | 1 (2) |
Disease control rate,* n (%) | 35 (70) | 32 (64) |
95% CI | 55.4 to 82.1 | 49.2 to 77.1 |
Median time to response (range),† months | 2.8 (1.3–33.1) | 2.7 (1.4–19.4) |
Median duration of response (95% CI),† months | 42.7 (27.7 to not estimable) | Not reached (21.9 to not estimable) |
*CR+PR+SD (for at least 12 weeks); 95% CI based on the Clopper-Pearson method.
†Evaluated in patients who had an objective response.
BICR, blinded independent central review; CR, complete response; NIVO, nivolumab; PR, partial response; RELA, relatlimab; SD, stable disease.